Skip to content

Homeopathy on primary care of cocaine-related disorders

Homeopathy on primary care of cocaine-related disorders - ---: ---

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-8mj2qf
Enrollment
Unknown
Registered
2019-11-06
Start date
2019-11-21
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mental and behavioural disorders due to use of cocaine

Interventions

60 patients will be randomly allocated to treatment sequence A: 6 weeks of homeopathy, followed by six weeks of placebo. 60 patients will be randomly allocated to treatment sequence B: 6 weeks of pla
Drug

Sponsors

Prefeitura do Município de Itajaí
Lead Sponsor
Universidade do Vale do Itajaí
Collaborator

Eligibility

Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Assist score for cocaine between 4 and 26.

Exclusion criteria

Exclusion criteria: Negative urinary benzoilecgonine detection (< 150 ng/mL).

Design outcomes

Primary

MeasureTime frame
During homeopathic treatment and comparing to placebo we expect to find a 12% reduction of the reported number of cocaine using days (registered by means of a timeline follow-back methodology). ;-

Secondary

MeasureTime frame
During homeopathic treatment and comparing to placebo we expect to find (assessed by Minnesota Cocaine Craving Scale): a lower percentage of positive benzoylecgonine samples; reduction in cocaine craving; reduction in daily craving episodes number; reduction in craving episodes mean duration; a greater patient perception of medication action favoring craving reduction. We expect to achieve treatment adherence greater than 50%. We also expect to find no significative difference between the percentage of Adverse Events during homeopathy or placebo use.

Countries

Brazil

Contacts

Public ContactUbiratan Adler

Unidade de Saúde Escola da Universidade Federal de São Carlos

ubiadler@outlook.com+55 16 3351-8926

Outcome results

None listed

Source: REBEC (via WHO ICTRP)